Pathogenesis and therapeutic strategy in platinum resistance lung cancer
- 1 August 2021
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1876 (1) , 188577
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82074069)
This publication has 146 references indexed in Scilit:
- A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2013
- Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapyLung Cancer, 2012
- Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapyCell Death & Differentiation, 2011
- Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch SignalingCancer Research, 2010
- Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancerLung Cancer, 2010
- Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2010
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsOncogene, 2009
- Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell TherapyJournal of Immunotherapy, 2008
- Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancerBMC Cancer, 2008
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005